Ceek.jp Altmetrics (α ver.)
  1. ホーム
  2. 文献一覧: Zhi LIU (著者)
  3. 2件

2 0 0 0 OA Neoerysiphe leontopodii sp. nov., a new powdery mildew from China

著者
Tie-Zhi Liu Li Liu Jing Wen Shu-Yan Liu
出版者
The Mycological Society of Japan
雑誌
Mycoscience (ISSN:13403540)
巻号頁・発行日
vol.64, no.6, pp.150-155, 2023-10-27 (Released:2023-11-20)
参考文献数
26
A powdery mildew was found on Leontopodium leontopodioides (Asteraceae) in China. Phylogenetic analyses using a combination of internal transcribed spacer and 28S rDNA sequences showed that this species, which clusters as sister to Neoerysiphe joerstadii, is allied to N. galii, N. geranii, and N. nevoi. This species differs from the closely allied N. joerstadii in the number and size of asci (3-10 asci, 55-75 × 20-40 µm versus 16-32 asci, 40-60 × 20-30 µm). This species is morphologically very similar to N. gnaphalii, but clearly differs from this species in having larger chasmothecia and colorless appendages. Therefore, the powdery mildew on L. leontopodioides is described as N. leontopodii sp. nov.

1 0 0 0 OA Effect of CYP3A5*3 Polymorphism on Pharmacokinetic Drug Interaction between Tacrolimus and Amlodipine

著者
Xiao-cong ZUO Ya-nan ZHOU Bi-kui ZHANG Guo-ping YANG Ze-neng CHENG Hong YUAN Dong-sheng OUYANG Shi-kun LIU Jeffrey S. BARRETT Pei-jiong LI Zhi LIU Hong-yi TAN Ren GUO Ling-yun ZHOU Yue-liang XIE Zuo-jun LI Jing LI Chun-jiang WANG Jiang-lin WANG
出版者
The Japanese Society for the Study of Xenobiotics
雑誌
Drug Metabolism and Pharmacokinetics (ISSN:13474367)
巻号頁・発行日
vol.28, no.5, pp.398-405, 2013 (Released:2013-10-25)
参考文献数
51
被引用文献数
19
The objective of this study was to evaluate the effect of the CYP3A5*3 allele on the pharmacokinetics of tacrolimus and amlodipine, and drug-drug interactions between them in healthy subjects. Pharmacokinetic drug interactions between tacrolimus and amlodipine were evaluated in a randomized, 3-period, 6-sequence crossover study in healthy Chinese volunteers according to CYP3A5 genotype. A single-dose and multiple-dose study were designed. A 96-h pharmacokinetic study followed either tacrolimus or amlodipine dose, and the washout periods between the study phases were 14 days. In the single-dose study, apparent oral clearance (CL/F) of tacrolimus (5 mg) in CYP3A5 expressers was 3.8-fold (p = 0.008) higher than that in CYP3A5 non-expressers. Amlodipine decreased mean tacrolimus CL/F in CYP3A5 expressers by 2.2-fold (p = 0.005), while it had no effect on that in CYP3A5 non-expressers. The CL/F of amlodipine in CYP3A5 non-expressers was 2.0-fold (p = 0.001) higher than that in CYP3A5 expressers. Tacrolimus increased mean amlodipine CL/F in CYP3A5 expressers by 1.4-fold (p = 0.016) while it had no effect on that in CYP3A5 non-expressers. Tacrolimus slightly reduced the AUC0–∞ of amlodipine in both CYP3A5 expressers and non-expressers. Dose adjustment of tacrolimus should be considered according to CYP3A5*3 genetic polymorphism when tacrolimus is coadministered with amlodipine.